DEA Proposes Moving Suvorexant, Lemborexant, and Daridorexant from Schedule IV to Schedule V

By Christopher Smoot, Founder & Editor · Last verified against source: August 16, 2026

More From This Agency

• DEA Temporarily Schedules Mitragynine Pseudoindoxyl, MGM-15, and MGM-16 as Schedule I Substances August 26, 2026
• Justice Department Establishes National Fraud Enforcement Division August 18, 2026

Plain-English Summary

The Drug Enforcement Administration is proposing to transfer the three sleep‑aid drugs suvorexant, lemborexant, and daridorexant from Schedule IV to Schedule V under the Controlled Substances Act. If the rule is finalized, the substances would be subject to the regulatory controls, civil penalties, and criminal sanctions that apply to Schedule V drugs. The proposal outlines that the change would affect anyone who manufactures, distributes, imports, exports, researches, teaches, analyzes, or possesses these drugs. The agency is seeking public comment on the proposal before it can be finalized.

Current Status

This is a proposed rule published for public comment and has not yet been finalized.

What This Means

The abstract states that the DEA would move the three named compounds into Schedule V, which carries the lowest level of control among scheduled drugs. Under Schedule V, the DEA’s enforcement focus shifts to lower‑level administrative and civil penalties for violations, with criminal sanctions generally limited to more serious offenses. Anyone who handles the drugs—whether manufacturing, distributing, importing, exporting, conducting research, teaching, or simply possessing them—must comply with Schedule V record‑keeping, labeling, and reporting requirements. The change would also affect the permissible quantities for personal use and could alter prescribing practices, as Schedule V substances often have fewer prescribing restrictions than Schedule IV. Finally, the proposal signals that the DEA will enforce the same sanctions it currently applies to other Schedule V substances if violations occur.

Who Is Affected

Pharmaceutical manufacturers that produce suvorexant, lemborexant, or daridorexant would need to adjust their compliance programs to meet Schedule V requirements. Distributors, pharmacies, and importers/exporters of these drugs must update labeling, record‑keeping, and reporting systems. Researchers and academic institutions conducting studies on these compounds will face a different regulatory review process. Healthcare providers prescribing the drugs may encounter altered prescribing limits and may need to educate patients about the new scheduling. Law‑enforcement and DEA compliance officers will oversee the transition and enforce the new schedule’s controls.

Background

The proposal responds to the Controlled Substances Act’s mandate to periodically review drug schedules based on abuse potential, medical use, and safety. Recent clinical data suggest that suvorexant, lemborexant, and daridorexant have a lower risk of dependence than many Schedule IV drugs, prompting the DEA to consider a downgrade. The agency’s review aligns with broader efforts to calibrate scheduling to reflect current scientific evidence and reduce unnecessary regulatory burdens. No specific prior regulatory action on these three drugs is cited, indicating this is the first formal scheduling reconsideration for them.

Arguments For

Proponents argue that the three insomnia agents have demonstrated a low abuse potential and a favorable safety profile, justifying a less restrictive schedule. Moving them to Schedule V would reduce compliance costs for manufacturers and distributors while maintaining sufficient oversight to prevent diversion.

Arguments Against

The abstract does not identify any organized opposition, and it indicates no substantial controversy surrounding the reclassification.

Economic Considerations

Because the abstract provides no official cost estimate, any economic analysis is speculative. A Schedule V designation could lower compliance expenses for companies by reducing record‑keeping and reporting burdens, potentially translating into lower drug prices. Conversely, entities that must re‑label or re‑configure inventory systems may incur short‑term transition costs. The broader market could see modest growth in prescribing if clinicians perceive the drugs as less tightly controlled, which might increase sales revenues for manufacturers. Overall, the net economic effect is uncertain pending a detailed impact assessment.

Sections beyond the plain-English summary are AI-synthesized analysis based on the sourced Federal Register filing, read, edited where needed, and approved by a human editor before publication. Full methodology: Editorial & Methodology.